[go: up one dir, main page]

WO2008039179A1 - Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c - Google Patents

Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c Download PDF

Info

Publication number
WO2008039179A1
WO2008039179A1 PCT/US2006/037231 US2006037231W WO2008039179A1 WO 2008039179 A1 WO2008039179 A1 WO 2008039179A1 US 2006037231 W US2006037231 W US 2006037231W WO 2008039179 A1 WO2008039179 A1 WO 2008039179A1
Authority
WO
WIPO (PCT)
Prior art keywords
ibogaine
composition
noribogaine
ibogamine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/037231
Other languages
English (en)
Inventor
Howard L. Lotsof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Addiction Research Institute Inc
Original Assignee
Addiction Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addiction Research Institute Inc filed Critical Addiction Research Institute Inc
Priority to EP06815317A priority Critical patent/EP2083825A4/fr
Priority to PCT/US2006/037231 priority patent/WO2008039179A1/fr
Priority to CA002664935A priority patent/CA2664935A1/fr
Publication of WO2008039179A1 publication Critical patent/WO2008039179A1/fr
Priority to IL197804A priority patent/IL197804A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to compositions for the treatment of Hepatitis. More specifically, the present invention is directed to a composition including ibogaine and/or noribogaine, and methods of using the same. Still more specifically, the present invention is directed to a composition and the use of a composition comprising one or more of ibogaine, its active salts and principal metabolite noribogaine to treat somatic complaints, elevated liver enzymes and viral load in patients with susceptible hepatitis C.
  • Hepatitis C is a member of the group of viruses known as Flaviviridae.
  • the virus was isolated from a blood-borne non-A, non-B viral hepatitis genome and is identified as nonA, nonB.
  • the virus duplicates by RNA replication and is prone to mutation.
  • Chronic HCV affects three to four million individuals in the United States and occurs in greater than 80 percent of the individuals infected with acute HCV. A minority of patients, approximately 15 percent, may clear the virus naturally.
  • the infection however, is lifelong in the majority of infected individuals and may be life threatening to them.
  • the virus is principally transferred through blood, though other vectors cannot be ruled out.
  • Subsets of the population including intravenous drug users and intravenous drug users in recovery may have chronic HCV infection rates of 70 to 90 percent.
  • Chronic HCV may progress rapidly or slowly and there is significant diversity of progression. Symptoms for chronic HCV tend to be nonspecific including fatigue, high ALT and AST levels, muscle and joint pain and right-upper-quadrant discomfort or tenderness of the liver.
  • HCV infection is a major risk factor for cirrhosis and liver cancer. An estimated 8,000 to 10,000 fatalities a year are caused by hepatitis C in the United States.
  • the principal conventional therapy for the treatment of chronic HCV is a therapy of interferon or pegylated interferon in combination with riboviron (as set forth in U.S . Patent Nos. 6,172,046 and 6,824,768). This therapy leaves much to be desired. Dose regimens, depending on genotype, are 24 or 48 weeks and may be required to be extended or repeated if not efficacious in obtaining a sustained virologic response (SVR) that is the desired outcome for this combination therapy.
  • SVR sustained virologic response
  • This therapy depending on the form and dose of interferon, the genotype of HCV and other factors, demonstrates efficacy of 2 percent to 75 percent.
  • Relapse depending on study, dose, genotype and other factors, may be as high as 48 percent in subjects who demonstrated a SVR at the completion of combination therapy.
  • Adverse events and side effects including possible fatal adverse events due to interferon riboviron combination therapy are significant.
  • Side effects and medication warnings consist of neuropsychiatric events that may include suicide, depression, return to drug abuse, psychosis, hallucinations, bipolar disorders and mania.
  • Other side effects may be bone marrow toxicity including cytopenias, thyroid disorders, hyperglycemia, diabetes; cardiovascular disorders including hypotension, arrhythmia, tachycardia, cardiomyopathy, angina pectoris and myocardial infarction.
  • interferon riboviron combination therapy Respiratory failure or collapse including death, fatal and nonfatal ulcerative hemorrhagic/ischemic colitis, abdominal pain, bloody diarrhea, fatal and nonfatal pancreatitis, rheumatoid arthritis, systemic lupus, loss of vision, retinopathy, and retinal hemorrhages. Anaphylaxis may occur and interferon riboviron combination therapy should be considered as a mutagen effecting DNA and as a possible carcinogen.
  • Interferon riboviron combination therapy is also dangerous to pregnant women directly and indirectly when used as a therapy in the significant other of a pregnant woman or a woman who may become pregnant. This therapy is anticipated to be an abortifacient.
  • Ibogaine, ibogamine and tabernanthine are among at least 12 alkaloids found in the Tabernanthe iboga plant of Gabon, West Africa.
  • the Gabonese, as well as Africans in other countries on that continent, have used the iboga alkaloids in the Bwiti religion and Mbiri medical societies principally during the last century or two by European accounts.
  • Ibogaine has also been used as an adjunctive agent in psychotherapy and psychoanalysis, and more recently has been described as an agent that may be able to suppress symptoms of dependence or withdrawal from drugs having dependence liability.
  • Discovery of this property of ibogaine led to the issuance of a number of U.S. patents to Howard S. Lotsof, including patents for ibogaine to treat narcotic dependency (U.S. Pat. No. 4,449,096), cocaine and amphetamine abuse (U.S. Pat. No. 4,587,243), alcohol dependency (U.S. Pat. No. 4,857,523), nicotine dependence (U.S. Pat. No. 5,026,697), poly-drug dependence (U.S. Pat. No. 5,152,994) and U.S. Patent No. 5,591,738 for the treatment of chemical dependence with combinations of iboga and betacarboline alkaloids.
  • iboga alkaloids are effective in treating hepatitis C symptoms, including liver swelling, increased ALT, AST and GGT levels and to reduce HCV RNA viral counts.
  • the present invention thus provides methods of treating somatic complaints, reducing liver enzyme values and reducing viral load of susceptible hepatitis C in animals by administering to a subject a therapeutically effective dose of iboga alkaloids comprising one or more of ibogaine, ibogamine, tabernanthine, their nontoxic salts and/or the converted principal metabolite noribogaine in a dose and time sufficient to accomplish those effects.
  • the present invention further provides for the administration of effective doses of the prodrug ibogaine, converted to noribogaine and producing plasma levels of ibogaine and/or noribogaine sufficient to reduce somatic complaints, liver enzyme levels and viral RNA in patients.
  • the present invention also provides effective doses and dose regimens of the prodrug ibogaine, its salts and therapeutic metabolites.
  • the present invention further provides for the administration of effective doses and dose regimens to be provided in single or multiple doses on a single day or over a period of days in therapeutically effective doses between 0.1 mg/kg and 25 mg/kg of the prodrug ibogaine, converted to noribogaine and producing plasma levels of ibogaine and/or noribogaine sufficient to reduce somatic complaints, liver enzyme levels and viral
  • compositions and methods of treating hepatitis C and hepatitis C-related complications comprise iboga alkaloids comprising one or more of ibogaine, ibogamine, tabernanthine, their nontoxic salts and/or the converted principal metabolite noribogaine in a therapeutic formulation.
  • the agents in the compositions are less harmful and less toxic than present anti-hepatitis C therapies.
  • compositions of the present invention and administering to the host a therapeutically effective amount of a composition of this invention are further disclosed.
  • the present invention further provides a method of treating somatic complaints, reducing liver enzyme values and reducing viral load of susceptible hepatitis C, comprising administering to a host a therapeutically effective amount of a composition of this invention.
  • Another aspect of the present invention is the shortness of the treatment period, as compared to existing therapies, in that the present treatment period may be a single day or a period of approximately two weeks.
  • the basis of the present invention is the finding that certain plants contain iboga alkaloids that assist in the treatment of hepatitis C and hepatitis C-related complications. This offers the advantage of allowing therapeutically effective doses of natural agents to be used as compared to the dose of synthetic substances that would be required in order to achieve the same or similar therapeutic effect.
  • natural agents extracted from the Tabernanthe iboga plant of Gabon, West Africa could be combined into one single formulation that would possess the ability to treat hepatitis C and hepatitis C-related complications.
  • the effective amount or effective dose is an amount of the composition to be administered to the host that treats hepatitis C and hepatitis C-related complications.
  • Suitable doses of a composition can be determined readily by various methods known to one skilled in the art, including generating an empirical dose-response curve, and other methods used in the pharmaceutical sciences.
  • the agents used in the compositions of this invention may be provided in the form of pure substances, or as root bark of the natural plant containing the natural agents in concentrations between about 1 to 6 per cent of which approximately fifty percent is ibogaine, or as concentrated plant extracts containing the natural agents in concentrations between about 5 to 40 percent of which one half is ibogaine. Doses of the root bark or total alkaloid extract would be extrapolated to correspond to doses of purified ibogaine in keeping with the dose recommendations and regimens for purified ibogaine and associated alkaloids as described in the present invention.
  • the amount of agent contained in a composition of this invention will depend in part on the desired results of the treatment, the stage of hepatitis C, its associated complications, and/or the health of the patient.
  • Another embodiment of the present invention includes improved methods for using the agents. It was discovered that various methods of administering the present invention to a host achieve therapeutically effective results, thus allowing therapeutically effective doses of agents to be administered to patients that suffer from various medical conditions, for example, conditions that make oral administration and digestion difficult. Until this invention, it was not known that the agents of the present invention could be administered by methods that would treat hepatitis C and hepatitis C-related complications in the host.
  • the present invention thus provides methods of treating hepatitis C and hepatitis C-related complications comprising administering a composition of this invention to a host in need of therapy.
  • the doses, routes of administration, and carriers and/or adjuvants used may vary based on the view of known procedures for treatment of hepatitis C and hepatitis C-related complications or the delivery of any manner of drug product known to those familiar with the art. 6 037231
  • composition can be administered in the form of a tablet, capsule or other pharmacologically appropriate carrier, in a parenteral solution, in a suppository, in a rectal solution, in the form of a tea, or in the form without plant material in a tablet, capsule, transdermal technology or other pharmacological carrier, in a parenteral solution, or in a suppository which contains at least one of the agents comprising iboga alkaloids.
  • compositions of this invention may also be administered as a solution and other oral or parenteral administration can be used.
  • a compound with poor solubility in acidic media may show poor or erratic bioavailability when absorbed orally.
  • intravenous administration requires that a drug be administered in a soluble form.
  • Compounds that are intended for oral administration but are susceptible to rapid degradation at low pH (i.e. gastric acids) will likely require protection from low pH environments like the stomach. Protection can often be afforded by administering the drug in a dosage form with an acid-resistant coating.
  • the compositions may also be administered as part of a formulation.
  • compositions of this invention can be used in the form of tablets, capsules, granules, powders, lozenges, syrups, elixirs, solutions, suspensions, and the like, in accordance with standard pharmaceutical practice.
  • a dried extract can be compounded into tablets, capsules, or other solid-dosage form.
  • a solubilized liquid formulation can be combined with syrup or other agent to formulate suspensions, solutions, elixirs, or tinctures to improve the taste, potency, or shelf life.
  • parenteral administration which includes intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the agents are usually prepared, and the pH of the solutions are suitably adjusted and buffered.
  • Carriers useful in formulating the preparations are commonly used pharmaceutically acceptable non-toxic carriers such as gelatin, lactose sodium citrate, salts of phosphoric acid, starch, magnesium stearate, sodium lauryl sulfate, talc, polyethylene glycol, etc.
  • the carrier may be used with other additives such as diluents, binders, buffer agents, preservatives, sweetening agents, flavoring agents, glazes, disintegrators, coating agents emulsifying agents, suspending agents, etc.
  • the dosage regimen may be regulated according to the potency of the individual agents utilized in the compositions of this invention, the mode of administration, and the needs of the host depending on factors such as the degree and severity of the disease state and age and general condition of the host being treated. Dosing ranges from 0.1 to 25 milligrams of the composition of the present invention per kilogram of body weight, once or multiple times daily, for one day to four weeks or longer depending upon the severity and length of hepatitis C infection and the response of the patient.
  • the present invention also provides methods of treating hepatitis C and related complications in the significant other or sexual partner of a pregnant female without having an observable toxic effect on the fetus.
  • a further embodiment of the present invention provides for the treatment of hepatitis C symptoms, including liver swelling, increased liver enzyme levels, including ⁇ -glutamyl transferase (GGT), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline Phosphatase levels, and for the reduction in HCV RNA viral counts.
  • Elevated levels of GGT, ALT, AST and Alkaline Phosphatase indicate injury or trauma to the liver.
  • reduced levels of GGT, AST, ALT and Alkaline Phosphatase indicate reduced trauma or injury of the liver.
  • Another embodiment of the present invention is that it can be effective in a chemically dependent population - a population which has greater tendency to be susceptible to hepatitis C infection.
  • Another embodiment of the present invention is that it can concurrently treat signs and symptoms of hepatitis C infection and chemical dependence disorders.
  • Example 1 A thirty-three year old male diagnosed as HCV positive and using 1/2 gram of heroin per day was administered 25 mg/kg of ibogaine HCl. Following the administration of ibogaine, heroin use ceased along with swelling of the liver and pain in the area of the liver.
  • AST was reduced from pretreatment level of 201 to post treatment level of 25.
  • ALT was reduced from pretreatment level of 410 to post treatment level of 50.
  • GGT level was reduced from 155 to 33.
  • Pretreatment Alkaline Phosphatase was 99, AST was 103 and ALT 195.
  • Post treatment Alkaline Phosphatase 88, AST 89 and ALT 127.
  • An additional 250 mg of ibogaine HCl further reduced HCV RNA IU/mL to 384,000.
  • a final dose within this regimen of 250 mg ibogaine was administered reducing the HCV RNA IU/mL to 154,000.
  • Example 4 A forty-two year old female weighing 160 lbs tested positive HCV RNA genotype
  • RNA IU/mL was 12,600,000. Subject was administered a total of 27 mg/kg of ibogaine HCl over a period of 48 hours in the following regimen: 2 mg/kg, 2 mg/kg, 2 mg/kg, 2 mg/kg, 2 mg/kg, 12 mg/kg, and 3 mg/kg. HCV RNA IU/mL was reduced to 50,100. Prior to ibogaine therapy patient's urine was dark and stool light. Post treatment color of urine and stool were normal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition qui comprend un indole alcaloïde, l'ibogaïne, ses sels actifs et son principal métabolite, la noribogaïne, forme dé-méthylée de l'ibogaïne, et qui est destinée au traitement de l'hépatite C et des complications liées à l'hépatite C lorsqu'elle est administrée dans des schémas à dose unique ou multiple efficaces pour réduire les symptômes somatiques, les valeurs des enzymes hépatiques et la charge virale causée par l'hépatite C chronique chez les patients. L'invention concerne également des procédés d'utilisation de ladite composition.
PCT/US2006/037231 2006-09-26 2006-09-26 Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c Ceased WO2008039179A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06815317A EP2083825A4 (fr) 2006-09-26 2006-09-26 Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c
PCT/US2006/037231 WO2008039179A1 (fr) 2006-09-26 2006-09-26 Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c
CA002664935A CA2664935A1 (fr) 2006-09-26 2006-09-26 Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c
IL197804A IL197804A0 (en) 2006-09-26 2009-03-25 Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/037231 WO2008039179A1 (fr) 2006-09-26 2006-09-26 Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c

Publications (1)

Publication Number Publication Date
WO2008039179A1 true WO2008039179A1 (fr) 2008-04-03

Family

ID=39230475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037231 Ceased WO2008039179A1 (fr) 2006-09-26 2006-09-26 Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c

Country Status (4)

Country Link
EP (1) EP2083825A4 (fr)
CA (1) CA2664935A1 (fr)
IL (1) IL197804A0 (fr)
WO (1) WO2008039179A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013048355A2 (fr) 2011-08-01 2013-04-04 Tataroglu Vedat Composition à base d'herbes pour traiter la maladie de l'hépatite c et procédé d'utilisation de cette composition à base d'herbes
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
WO2015134405A1 (fr) * 2014-03-03 2015-09-11 Demerx, Inc. Utilisations therapeutiques de l'ibogaïne et composes associes
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
JP2018142967A (ja) * 2012-07-11 2018-09-13 スカイワークスフィルターソリューションズジャパン株式会社 電子部品
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US20200078367A1 (en) * 2014-03-03 2020-03-12 Demerx, Inc. Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12097293B2 (en) 2019-10-14 2024-09-24 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12409132B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5152994A (en) * 1990-05-31 1992-10-06 Lotsof Howard S Rapid method for interrupting or attenuating poly-drug dependency syndromes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408719B (de) * 2000-03-22 2002-02-25 Nowicky Wassili Mittel zur behandlung von hepatitis c

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5152994A (en) * 1990-05-31 1992-10-06 Lotsof Howard S Rapid method for interrupting or attenuating poly-drug dependency syndromes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARFEIN R.S. ET AL., AMERICAN JOURNAL OF PUBLIC HEALTH, vol. 86, no. 5, May 1996 (1996-05-01), pages 655 - 661, XP008110246 *
See also references of EP2083825A4 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013048355A2 (fr) 2011-08-01 2013-04-04 Tataroglu Vedat Composition à base d'herbes pour traiter la maladie de l'hépatite c et procédé d'utilisation de cette composition à base d'herbes
US8993578B2 (en) 2011-10-21 2015-03-31 Abbvie Inc. Methods for treating HCV
US9452194B2 (en) 2011-10-21 2016-09-27 Abbvie Inc. Methods for treating HCV
US8680106B2 (en) 2011-10-21 2014-03-25 AbbVic Inc. Methods for treating HCV
US8685984B2 (en) 2011-10-21 2014-04-01 Abbvie Inc. Methods for treating HCV
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US8969357B2 (en) 2011-10-21 2015-03-03 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP2018142967A (ja) * 2012-07-11 2018-09-13 スカイワークスフィルターソリューションズジャパン株式会社 電子部品
WO2015134405A1 (fr) * 2014-03-03 2015-09-11 Demerx, Inc. Utilisations therapeutiques de l'ibogaïne et composes associes
US20200078367A1 (en) * 2014-03-03 2020-03-12 Demerx, Inc. Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
US11077118B2 (en) 2014-09-12 2021-08-03 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11149044B2 (en) 2017-10-09 2021-10-19 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en) 2017-10-09 2024-03-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10947257B2 (en) 2017-10-09 2021-03-16 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11180517B2 (en) 2017-10-09 2021-11-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en) 2017-10-09 2022-11-22 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en) 2017-10-09 2023-04-18 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12312375B2 (en) 2017-10-09 2025-05-27 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11851451B2 (en) 2017-10-09 2023-12-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10954259B1 (en) 2017-10-09 2021-03-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11738035B2 (en) 2019-04-17 2023-08-29 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US12433904B2 (en) 2019-04-17 2025-10-07 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12447164B2 (en) 2019-04-17 2025-10-21 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12409132B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12097293B2 (en) 2019-10-14 2024-09-24 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Also Published As

Publication number Publication date
EP2083825A4 (fr) 2009-11-04
CA2664935A1 (fr) 2008-04-03
IL197804A0 (en) 2009-12-24
EP2083825A1 (fr) 2009-08-05

Similar Documents

Publication Publication Date Title
EP2083825A1 (fr) Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c
US20060229293A1 (en) Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
WO2001062295A1 (fr) Medicaments contenant des ingredients actifs combines
EP3991729A1 (fr) Utilisation de l'amlexanox dans la préparation d'un médicament contre le virus de l'hépatite
EP4209209A1 (fr) Application de luméfantrine et de dérivés de celle-ci dans le traitement d'une infection par coronavirus
CN111265527A (zh) 萘酚喹及其药学上可接受的盐在制备抗冠状病毒药物中的用途
EP2252286B1 (fr) Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artemisinine ou l'un de ses derives pour le traitement du paludisme severe
JPH03170475A (ja) 抑うつ症治療剤
CN108904484A (zh) 一种没食子酸乙酯的用途
CN116367834A (zh) 包含衣壳蛋白抑制剂和核苷类似物的药物组合
JP3885135B2 (ja) Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
JP2005500995A (ja) Ｂ型肝炎ウイルスにより起きる感染症の治療または予防のためのフィランタス属構成部分の使用
CN115105519A (zh) 用于治疗乙型肝炎的药物组合物及其制备方法
CN114272254A (zh) 甘草次酸和芍药苷的组合在治疗肝损伤、肝纤维化中的应用
CN106822152B (zh) 一种药物组合物及其应用
JPH11508247A (ja) ウベニメクス及びウベニメクスを含む医薬組成物のウイルス性肝炎の治療薬としての用途
CN110575447A (zh) 一种用于防治糖尿病的药物组合物及其用途
WO2019232740A1 (fr) Composition pharmaceutique destinée à prévenir le diabète et utilisation correspondante
WO2009084732A1 (fr) Agent servant à soulager les effets secondaires néfastes d'une thérapie de combinaison interféron/ribavirine
US12336996B2 (en) Drug combination containing TLR7 agonist
JP2857388B1 (ja) アカメガシワ樹皮のエキスを有効成分とする肝機能改善剤、肝機能改善飲料、及び肝機能改善茶
AU716760B2 (en) Aids therapeutic composition
CN119033794A (zh) 胆酸和非诺贝特在流感病毒感染中的应用
CN100464748C (zh) 消旋去甲胡桐素a制备抗爱滋病毒类药物的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06815317

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2664935

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006815317

Country of ref document: EP